This poster describes a study of a state Medicaid population, examining heart failure-related hospitalizations and emergency department(ED) visits to the treatment cost of managing heart failure pre- and post-sacubitril/valsartan initiation. Previous studies showed that patients who were treated with sacubitril/valsartan had lower rates of hospitalizations and costs. However, studies of the economic impact of sacubitril/valsartan for the Medicaid population is limited. This study concludes that the overall benefit (cost avoidance in hospitalizations/ED visits) did not outweigh the additional costs of sacubitril/valsartan. However, members that are more adherent to sacubitril/valsartan did have an overall benefit that outweighs the additional cost of sacubitril/valsartan.
Poster
Cost-Benefit Analysis of Sacubitril/Valsartan Among Patients with Heart Failure with Reduced Ejection Fraction in a Medicaid Population
Alan Gabot
Pavel Lavitas, PharmD, BCPS
Clinical Team Lead, Clinical Pharmacy Services
Thomas Pomfret, PharmD, MPH, BCPS
Clinical Consultant Pharmacist Team Lead and Residency Program Director, Clinical Pharmacy Services
Mckenzie Taylor, PharmD
Managed Care Pharmacy Resident, Clinical Pharmacy Services
Karen Stevens, PharmD
Clinical Consultant Pharmacist, Clinical Pharmacy Services
Andrew Coelho
Clinical Consultant Pharmacist, Clinical Pharmacy Services
Bonnie C. Greenwood, PharmD, BCPS
Director, Clinical Programs, Clinical Pharmacy Services
Karen Clements, ScD
Senior Project Director, Research and Evaluation
Kimberly Lenz, PharmD, MBA, FAMCP
Senior Pharmacy Director, MassHealth/Office of Clinical Affairs
